These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 23075915)

  • 21. Pharmacokinetic interaction of telmisartan with s-amlodipine: an open-label, two-period crossover study in healthy Korean male volunteers.
    Noh YH; Lim HS; Kim MJ; Kim YH; Choi HY; Sung HR; Jin SJ; Lim J; Bae KS
    Clin Ther; 2012 Jul; 34(7):1625-35. PubMed ID: 22721873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.
    Kakuda TN; Van Solingen-Ristea R; Aharchi F; Smedt GD; Witek J; Nijs S; Vyncke V; Hoetelmans RM
    J Clin Pharmacol; 2013 Jan; 53(1):41-50. PubMed ID: 23400742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s.
    Kiser JJ; Lu D; Rosenkranz SL; Morse GD; DiFrancesco R; Sherman KE; Butt AA;
    Drugs R D; 2017 Dec; 17(4):557-567. PubMed ID: 28875397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir.
    Johnson M; Borland J; Chen S; Savina P; Wynne B; Piscitelli S
    Br J Clin Pharmacol; 2014 Nov; 78(5):1043-9. PubMed ID: 24838177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Steady-state pharmacokinetics of etravirine and lopinavir/ritonavir melt extrusion formulation, alone and in combination, in healthy HIV-negative volunteers.
    Schöller-Gyüre M; Kakuda TN; Witek J; Akuma SH; De Smedt G; Spittaels K; Vyncke V; Hoetelmans RM
    J Clin Pharmacol; 2013 Feb; 53(2):202-10. PubMed ID: 23436265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers.
    Peytavin G; Gautran C; Otoul C; Cremieux AC; Moulaert B; Delatour F; Melac M; Strolin-Benedetti M; Farinotti R
    Eur J Clin Pharmacol; 2005 Jun; 61(4):267-73. PubMed ID: 15889300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies.
    Kakuda TN; Woodfall B; De Marez T; Peeters M; Vandermeulen K; Aharchi F; Hoetelmans RM
    J Antimicrob Chemother; 2014 Mar; 69(3):728-34. PubMed ID: 24155058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
    DeJesus E; Lalezari JP; Osiyemi OO; Ruane PJ; Ryan R; Kakuda TN; Witek J
    Antivir Ther; 2010; 15(5):711-20. PubMed ID: 20710052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
    J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions.
    Spínola AC; Almeida S; Filipe A; Neves R; Trabelsi F; Farré A
    Clin Ther; 2009 Sep; 31(9):1992-2001. PubMed ID: 19843489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.
    Poizot-Martin I; Bellissant E; Garraffo R; Colson P; Piroth L; Solas C; Renault A; Bourlière M; Halfon P; Ghosn J; Alric L; Naqvi A; Carrieri P; Molina JM;
    HIV Clin Trials; 2016 Mar; 17(2):63-71. PubMed ID: 27077673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir.
    Gutierrez-Valencia A; Ruiz-Valderas R; Torres-Cornejo A; Viciana P; Espinosa N; Castillo-Ferrando JR; Lopez-Cortes LF
    Clin Infect Dis; 2014 Jan; 58(2):268-73. PubMed ID: 24145880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers.
    Peeters M; Janssen K; Kakuda TN; Schöller-Gyüre M; Lachaert R; Hoetelmans RM; Woodfall B; De Smedt G
    Ann Pharmacother; 2008 Jun; 42(6):757-65. PubMed ID: 18445705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study.
    Lê MP; Valantin MA; Assoumou L; Soulie C; Le Mestre S; Weiss L; Yazdanpanah Y; Molina JM; Bouchaud O; Raffi F; Reynes J; Calvez V; Marcelin AG; Costagliola D; Katlama C; Peytavin G;
    Pharmacotherapy; 2019 Apr; 39(4):514-520. PubMed ID: 30815916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.
    Moltó J; Curran A; Miranda C; Challenger E; Santos JR; Ribera E; Khoo S; Valle M; Clotet B
    J Antimicrob Chemother; 2018 Mar; 73(3):732-737. PubMed ID: 29237008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioavailability and tolerability of combination treatment with revaprazan 200 mg + itopride 150 mg: a randomized crossover study in healthy male Korean volunteers.
    Choi HY; Noh YH; Jin SJ; Kim YH; Kim MJ; Sung H; Jang SB; Lee SJ; Bae KS; Lim HS
    Clin Ther; 2012 Sep; 34(9):1999-2010. PubMed ID: 22858177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.
    Kakuda TN; Wade JR; Snoeck E; Vis P; Schöller-Gyüre M; Peeters MP; Corbett C; Nijs S; Vingerhoets J; Leopold L; De Smedt G; Woodfall BJ; Hoetelmans RM
    Clin Pharmacol Ther; 2010 Nov; 88(5):695-703. PubMed ID: 20881958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone.
    Schöller-Gyüre M; Kakuda TN; Woodfall B; Aharchi F; Peeters M; Vandermeulen K; Hoetelmans RM
    Contraception; 2009 Jul; 80(1):44-52. PubMed ID: 19501215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects.
    Shin D; Kim TE; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Curr Med Res Opin; 2012 Jul; 28(7):1213-20. PubMed ID: 22697273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers.
    Boffito M; Jackson A; Lamorde M; Back D; Watson V; Taylor J; Waters L; Asboe D; Gazzard B; Pozniak A
    J Acquir Immune Defic Syndr; 2009 Oct; 52(2):222-7. PubMed ID: 19620877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.